Spotlight on Cefditoren Pivoxil in Bacterial Infections

Dubois J, St-Pierre C. Superior inhibitory and bactericidal activity of cefditoren against respiratory tract pathogens [poster no. 370]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto Peric M, Browne FA, Jacobs MR, et al. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents. Clin Ther 2003 Jan; 25(1): 169–77 Seki H, Kasahara Y, Ohta K, et al. Antimicrobial activities of cefditoren against respiratory pathogens isolated from children in Japan. J Infect Chemother 1999 Mar; 5(1): 16–20 Sahm DF, Draghi D, Blosser RS, et al. Comparative activities of cefditoren and other antimicrobials against recent clinical isolates of non-pneumococcal streptococci collected throughout the United States [poster no. 375]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto Granizo JJ, Fernandez-Roblas R, Coronel P, et al. In vitro susceptibility of 590 isolates of S. pyogenes against cefditoren and 10 other antimicrobials: a multicenter international study in Southern Europe (ARISE Project) [abstract no. P1 368]. Clin Microbiol Infect 2002 Apr; 8Suppl. 1: 320 Jones RN, Biedenbach DJ, Croco MAT, et al. In vitro evaluation of a novel orally administered cephalosporin (cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. Diagn Microbiol Infect Dis 1998; 31: 573–8 Kelly LM, Jacobs MR, Appelbaum PC. Comparison of agar dilution, microdilution, E-test, and disk diffusion methods for testing activity of cefditoren against Streptococcus pneumoniae. J Clin Microbiol 1999; 37(10): 3296–9 Fuchs PC, Barry AL, Brown SD. Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to cefditoren, and provisional interpretive criteria. Diagn Microbiol Infect Dis 2000; 37: 265–9 Ednie LM, Pankuch GA, Jacobs MR, et al. Activity of cefditoren compared with other agents against quinolone and macrolide susceptible and resistant pneumococci [poster no. 378]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto Beyer J, Shortridge V, Flamm R, et al. In vitro activity of cefditoren against clinical isolates of S. pneumoniae, H. influenzae, and M. Catarrhalis [poster no. 376]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto Clark CL, Nagai K, Dewasse BE, et al. Activity of cefditoren against respiratory pathogens. J Antimicrob Chemother 2002 Jul; 50(1): 33–41 Karlowsky JA, Jones ME, Draghi DC, et al. In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren. Diagn Microbiol Infect Dis 2002 Jan; 42(1): 59–64 Soriano F, Granizo JJ, Fenoll A, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four southern European countries (ARISE project) from adult patients: results from the cefditoren surveillance program. J Chemother 2003 Apr; 15(2): 107–12 Johnson DM, Biedenbach DJ, Beach ML, et al. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. Diagn Microbiol Infect Dis 2000; 37 (2): 99–105 Sahm DF, Karlowsky JA, Draghi D, et al. Comparative activities of cefditoren and other antimicrobials against recent clinical isolates of H influenzae and M. catarrhalis collected throughout the United States [poster no. 369]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto Karlowsky JA, Critchley IA, Draghi DC, et al. Activity of cefditoren against β-lactamase-positive and -negative Haemophilus influenzae and Moraxella catarrhalis. Diagn Microbiol Infect Dis 2002 Jan; 42(1): 53–8 Soriano F, Granizo JJ, Coronel P, et al. Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries: the ARISE project. Int J Antimicrob Agents 2004 Mar; 23(3): 296–9 Nishi J, Yoshinaga M, Tokuda K, et al. Oral antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates from Japanese children. Int J Antimicrob Agents 2002; 20: 130–5 Ehrhardt AF, Moland ES, Sanders CC. Impact of specific β-lactamase and β-lactamase/porin combinations on the in vitro activity of cefditoren in a genetically defined panel [poster no. 374]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto Medeiros AA. Comparison of oral cephalosporins and their activity against β-lactamase-producing bacteria. Infect Dis Clin Pract 1998 Nov; 7Suppl. 4: S273–9 Jones RN, Pfaller MA, Jacobs MR, et al. Cefditoren in vitro activity and spectrum: a review of international studies using reference methods. Diagn Microbiol Infect Dis 2001; 41(1–2): 1–14 Guay DR. Review of cefditoren, an advanced-generation, broad-spectrum oral cephalosporin. Clin Ther 2001 Dec; 23(12): 1924–37 Mulford D, Mayer M, Witt G. Effect of age and gender on the pharmacokinetics of cefditoren [poster no. 310]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto Mulford D, Mayer M, Witt G. Effect of renal impairment on the pharmacokinetics of cefditoren [poster no. 311]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto Mayer M, Mulford D, Witt G. Effect of hepatic impairment on the pharmacokinetics of cefditoren [poster no. 312]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto Mayer M, Mulford D, Witt G. Effect of an H2 receptor antagonist or an antacid on the pharmacokinetics of cefditoren [poster no. 313]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto Purdue Pharmaceutical Products L.P. Package insert: Spectracef® tablets (cefditoren pivoxil) [online]. Available from URL: http://www.pharma.com/PI/Prescription/spectracef.pdf [Accessed 2004 Aug 23] Kinzig-Schippers M, Hinder M, Göhler K, et al. Tissue penetration of cefditoren (CEE) into bronchial mucosa (BM) and epithelial lining fluid (ELF) in patients undergoing fiberoptic bronchoscopy [abstract no. 946]. 41st Interscience Conference on Antimicrobials Agents and Chemotherapy; 2001 Dec 16–19; Chicago, 24 Mayer M, Mulford D, Witt G. Pharmacokinetics of cefditoren in blister fluid and plasma [abstract no. 656]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto, 20 Tedec-Meiji Farma S.A. Summary of product characteristics: Spectracef® filmcoated tablets. Madrid: Tedec-Meiji Farma S.A., 2004 Henry DC, Poling TL, Bettis RB, et al. A double-blind, randomized study of cefditoren vs cefuroxime for AECB. J Respir Dis 2001; 22 (8 Suppl.): S69–74 Tucker R, Rhudy J, Hunt B, et al. Safety and efficacy of cefditoren in acute exacerbation of chronic bronchitis (AECB) [abstract no. 836 plus poster]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto, 495 Tedec-Meiji Farma S.A. Efficacy of cefditoren-pivoxil compared to cefuroximeaxetil in patients with acute exacerbation of chronic bronchitis in adults. Tedec-Meiji Farma S.A., 2001 (Data on file) Fogarty CM, Cyganowski M, Palo WA, et al. A comparison of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study. Clin Ther 2002 Nov; 24(11): 1854–70 van Zyl L, le Roux JG, LaFata JA, et al. Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: results of a multicenter, prospective, randomized, double-blind study. Clin Ther 2002 Nov; 24(11): 1840–53 Comparative safety and efficacy of cefditoren pivoxil and Augmentin® (amoxicillin/clavulanate potassium) in the treatment of patients with acute maxillary sinusitis. TAP Holdings Inc., 1999 (Data on file) Multicentre, prospective, comparative, phase III study of cefditoren-pivoxil (CDTR-PI) versus cefuroxime-axetil in the treatment of acute community-acquired sinusitis (ACAS) in adults. Tedec-Meiji Farma S.A., 2001 (Data on file) Gooch W, Marsh D, Stickler T, et al. Cefditoren is safe and effective treatment for streptococcal pharyngitis [abstract no. 837 plus poster]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto, 495 Multicentre phase III, randomised, comparative study: cefditoren pivoxil (ME1207) with penicillin V in the treatment of acute bacterial pharyngotonsillitis in adults. Tedec-Meiji Farma S.A., 2001 (Data on file) Bucko AD, Hunt BJ, Kidd SL, et al. Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg bid with either cefuroxime 250 mg bid or cefadroxil 500 mg bid for the treatment of uncomplicated skin and skin-structure infections. Clin Ther 2002; 24(7): 1134–47 Brass EP. Pivalate-generating prodrugs and carnitine homeostasis in man. Pharmacol Rev 2002; 54(4): 589–98 Brass EP, Mayer MD, Mulford DJ, et al. Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil. Clin Pharmacol Ther 2003 Apr; 73(4): 338–47